Amylyx Pharmaceuticals, Inc. (AMLX)
Largest Insider Buys in Sector
AMLX Stock Price History Chart
AMLX Stock Performance
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Activity of Amylyx Pharmaceuticals, Inc.
Over the last 12 months, insiders at Amylyx Pharmaceuticals, Inc. have bought $437,194 and sold $563,850 worth of Amylyx Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Amylyx Pharmaceuticals, Inc. have bought $16.69M and sold $12.56M worth of stock each year.
Highest buying activity among insiders over the last 12 months: MILNE GEORGE M JR (director) — $879,200. FRATES JAMES M (Chief Financial Officer) — $304,104. Firestone Karen (director) — $106,590.
The last purchase of 40,000 shares for transaction amount of $101,368 was made by FRATES JAMES M (Chief Financial Officer) on 2024‑09‑12.
List of Insider Buy and Sell Transactions, Amylyx Pharmaceuticals, Inc.
| 2025-01-06 | Sale | Co-Chief Executive Officer | 7,471 0.0112% | $4.05 | $30,232 | -12.37% | ||
| 2025-01-06 | Sale | Co-Chief Executive Officer | 7,471 0.0112% | $4.04 | $30,202 | -12.37% | ||
| 2024-12-02 | Sale | Chief Medical Officer | 5,421 0.0078% | $5.54 | $30,007 | -26.67% | ||
| 2024-09-30 | Sale | Co-Chief Executive Officer | 18,589 0.0156% | $3.20 | $59,414 | +41.82% | ||
| 2024-09-30 | Sale | Co-Chief Executive Officer | 18,589 0.0156% | $3.20 | $59,429 | +41.82% | ||
| 2024-09-30 | Sale | Chief Medical Officer | 11,442 0.0096% | $3.20 | $36,559 | +41.82% | ||
| 2024-09-30 | Sale | Chief Legal Officer | 8,709 0.0073% | $3.20 | $27,840 | +41.82% | ||
| 2024-09-12 | Chief Financial Officer | 40,000 0.0267% | $2.53 | $101,368 | +67.27% | |||
| 2024-09-05 | director | 50,000 0.0281% | $2.13 | $106,590 | +85.45% | |||
| 2024-09-03 | director | 100,000 0.0579% | $2.20 | $219,800 | +88.43% | |||
| 2024-05-15 | Sale | Chief Legal Officer | 10,455 0.0052% | $1.88 | $19,654 | +44.78% | ||
| 2024-05-15 | director | 2,250 0.0011% | $1.89 | $4,252 | +44.78% | |||
| 2024-05-14 | director | 2,750 0.0014% | $1.89 | $5,184 | +40.11% | |||
| 2024-03-05 | Sale | Co-Chief Executive Officer | 4,135 0.0204% | $18.73 | $77,440 | -86.26% | ||
| 2024-03-05 | Sale | Co-Chief Executive Officer | 4,135 0.0204% | $18.73 | $77,440 | -86.26% | ||
| 2024-03-05 | Sale | Chief Financial Officer | 1,792 0.0088% | $18.73 | $33,560 | -86.26% | ||
| 2024-03-05 | Sale | Chief Legal Officer | 1,540 0.0076% | $18.73 | $28,841 | -86.26% | ||
| 2024-02-23 | Sale | Chief Legal Officer | 2,838 0.014% | $18.76 | $53,231 | -85.16% | ||
| 2024-01-09 | Sale | Co-Chief Executive Officer | 5,841 0.0251% | $16.33 | $95,372 | -82.44% | ||
| 2024-01-09 | Sale | Co-Chief Executive Officer | 5,841 0.0251% | $16.33 | $95,372 | -82.44% |
Insider Historical Profitability
| Cohen Joshua B | Co-Chief Executive Officer | 3213098 3.7496% | $3.60 | 0 | 6 | |
| Klee Justin B. | Co-Chief Executive Officer | 3176788 3.7073% | $3.60 | 0 | 6 | |
| MILNE GEORGE M JR | director | 858571 1.0019% | $3.60 | 2 | 1 | +36.36% |
| FRATES JAMES M | Chief Financial Officer | 233464 0.2724% | $3.60 | 1 | 5 | |
| Mazzariello Gina | Chief Legal Officer | 142768 0.1666% | $3.60 | 0 | 6 | |
| Bedrosian Camille L | Chief Medical Officer | 138380 0.1615% | $3.60 | 0 | 2 | |
| Firestone Karen | director | 55000 0.0642% | $3.60 | 3 | 0 | <0.0001% |
| Quimi Daphne | director | 5000 0.0058% | $3.60 | 2 | 0 | |
| Morningside Venture Investments Ltd | 10 percent owner | 6997302 8.1658% | $3.60 | 1 | 10 | +23.76% |
| ALS Invest 1 B.V. | 5937577 6.9291% | $3.60 | 0 | 1 | ||
| VIKING GLOBAL INVESTORS LP | 2300000 2.6841% | $3.60 | 1 | 0 | +23.76% | |
| Olinger Margaret | Chief Commercial Officer | 214355 0.2501% | $3.60 | 1 | 1 | +36.36% |
| Yeramian Patrick D | Chief Medical Officer | 205605 0.2399% | $3.60 | 0 | 5 | |
| Cheng Isaac | director | 6578 0.0077% | $3.60 | 1 | 0 | +36.36% |
| FONTEYNE PAUL R. | director | 3947 0.0046% | $3.60 | 1 | 0 | +36.36% |